CINRYZE® (C1 esterase inhibitor [human]) was the first FDA-approved preventive treatment that can start at age 6.

Start with HAE attack prevention.

CINRYZE Patient Brochure

This overview of CINRYZE can help patients understand how CINRYZE works, whether a C1-INH preventive therapy might be right for them, and what to expect from therapy.

Download now

CINRYZE Self-Administration Instructions

After you teach patients how to self-administer CINRYZE therapy, share this brochure which features step-by-step illustrated instructions, for additional at-home support.

Download now

Takeda advises the patient to receive training from a healthcare professional prior to self-administration.

Getting Started With Takeda Patient Support

Tailored product support for your patients prescribed HAE therapy

Supporting patients with HAE and prescribers for over 16 years

Our services include:

  • Benefits investigation to help determine your patient's insurance benefits and eligibility for certain services
  • Specialty pharmacy (or site of care) triage and coordination
  • Enrollment in the Takeda Patient Support Co-Pay Assistance Program, if they are eligible*
  • Arrange for Takeda product administration training (at home, if requested by your office) and education for your patient
  • Information about financial assistance options, if they're eligible*

*To be eligible, your patient must be enrolled in Takeda Patient Support and have commercial insurance. Other terms and conditions apply. Contact us for more details.

Need assistance?

Our support specialists are never more than a tap or a call away—1-866-888-0660, Monday through Friday, 8:30 AM to 8:00 PM ET.

Need to enroll your patient? Visit TakedaPatientSupport.com/HCP for more information. You can enroll your patient by faxing the completed Start Form.

If English is not your patient’s preferred language, we may be able to assist them in a language of their choosing.

Definition:

Dismiss